Artificial-Intelligence Powered Prostate Cancer Diagnosis Tool Launched

An advanced artificial-intelligence-powered prostate cancer diagnosis tool for pathologists has been launched by the Singapore-based company - Qritive, which is the leading provider of digital pathology solutions. Prostate adenocarcinoma develops in the gland cells that line the prostate gland and the tubes of the prostate gland. It is the most common type of prostate cancer. Nearly everyone with prostate cancer has this type. Symptoms may include a frequent urge to urinate, painful urination and ejaculation, and blood in the semen.

Prostate cancer is often diagnosed by performing a digital rectal exam (DRE), through a prostate-specific antigen (PSA) blood test, through a prostate biopsy, or with a CT scan. To make the diagnosis more accurate, the QAi Prostate tool developed with help of artificial intelligence analyzes whole slide images of prostate core needle biopsies.

How is Artificial Intelligence Useful in Prostate Cancer?

Making use of biopsy specimens in such a way identifies prostatic adenocarcinoma regions, and segments and classifies them into benign and malignant areas. After identifying and classifying the benign and malignant tumor areas in biopsy tissue samples, the QAi Prostate tool provides a detailed summary explaining the tumor size and percentage for each slide or ROI.

This helps pathologists make a more informed and accurate diagnosis quickly, thereby reducing the time to treatment for patients. Capabilities central to the QAi Prostate module include intelligent AI-based tumor classification; enriched and detailed AI summary and automated screening.

QAi Prostate was developed using a rich dataset and has undergone testing and validation to ensure its clinical metrics and reliability. It can work with any standard digital pathology system and can be easily integrated into existing workflows using an Open API interface through a customizable middleware.

It includes secured communication using standard SSL encryption and the middleware as a single point of entry with role-based access to ensure advanced security and compliance. QAi Prostate can be deployed for research use or as a laboratory-developed test only. It is currently not approved by the FDA or CE marked.

This technology has the potential to improve the accuracy and speed of prostate cancer diagnosis significantly, leading to better outcomes for patients. The launch of QAi Prostate is part of Qritive's ongoing commitment to innovation to provide the best clinical AI solutions for cancer diagnosis and advance health equity.

The company is dedicated to empowering healthcare professionals across the globe with AI-powered solutions to operate collaboratively at the peak of their performance despite complexity and distance.



Source-Medindia